Efficacy evaluation of extravesicle, derived from Wharton's jelly's mesenchymal cells of the umbilical cord, injection in androgenetic alopecia.

Efficacy and safety evaluation of extravesicle, derived from Wharton's jelly's mesenchymal cells of the umbilical cord, injection in androgenetic alopecia.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140624018210N13

Enrollment

Registered

2022-09-03

Start date

2022-10-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia. Androgenic alopecia

Interventions

Intervention group: a group of 10 people is treated with extravesicle solution derived from Wharton's jelly's mesenchymal cells of the umbilical cord.The treatment sessions are three sessions with an

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Ladies and gentlemen with androgenetic alopecia Age 18 years and above and less than 50 years old Hamilton score 2 to 5 in men Ludwig score 1 to 3 in women Complete patient consent to participate in the project

Exclusion criteria

Exclusion criteria: Platelet dysfunction Thrombocytopenia Anticoagulant drug use Malignancy Chemotherapy within 5 years Sepsis Smoking Pregnancy Ulcer or infection at the site of treatment Do not receive any topical or systemic medication in the last 3 months Women with hyperprolactinemia Women with hormonal dysfunction or polycystic ovarian disease

Design outcomes

Primary

Measure	Time frame
Alopecia severity. Timepoint: Before the start of the trial and two months after the last session. Method of measurement: Rate of change in the clinical severity of alopecia is measured by imaging with visioface. hamilton scale 1 to 6 in men.Ludwig scale 1 to 3 in women.;The amount of hair in the telogen phase. Timepoint: Before the beginning of the trial and two months after the last session. Method of measurement: The amount of hair in the telogen phase is measured by pull test.;Hair density. Timepoint: Before the beginning of the trial and two months after the last session. Method of measurement: Hair density is measured by trichoscan.;Patient satisfaction of treatment. Timepoint: Two months after the last session of treatment. Method of measurement: Patient global assessment score.;Physician satisfaction of treatment. Timepoint: Two months after the last session of treatment. Method of measurement: Physician global assessment score.	—

Measure

Time frame

Alopecia severity. Timepoint: Before the start of the trial and two months after the last session. Method of measurement: Rate of change in the clinical severity of alopecia is measured by imaging with visioface. hamilton scale 1 to 6 in men.Ludwig scale 1 to 3 in women.;The amount of hair in the telogen phase. Timepoint: Before the beginning of the trial and two months after the last session. Method of measurement: The amount of hair in the telogen phase is measured by pull test.;Hair density. Timepoint: Before the beginning of the trial and two months after the last session. Method of measurement: Hair density is measured by trichoscan.;Patient satisfaction of treatment. Timepoint: Two months after the last session of treatment. Method of measurement: Patient global assessment score.;Physician satisfaction of treatment. Timepoint: Two months after the last session of treatment. Method of measurement: Physician global assessment score.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Elham Behrangi

Iran University of Medical Sciences

behrangi.e@iums.ac.ir+98 21 6650 2040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026